Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.48 |
| ▸ | SORD | Q00796 | 4/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956331 | 0.82 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL4815499 | 0.79 | TRPV1 (0.64) | TRPV1SORDOGA | |
| SCHEMBL20956371 | 0.78 | TRPV1 (0.41) | TRPV1SORD | |
| SCHEMBL20956382 | 0.74 | SORD (0.36) | TRPV1SORD | |
| SCHEMBL20475492 | 0.72 | ME2 (0.49) | OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL20956346 | 0.72 | CDK4 (0.35) | TRPV1 | |
| SCHEMBL21193615 | 0.71 | TRPV1 (0.62) | TRPV1SORD | |
| SCHEMBL20991838 | 0.71 | CCNT1 (0.48) | TRPV1SORD | |
| SCHEMBL15205402 | 0.71 | AKR1C3 (0.50) | OGAOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL23235686 | 0.71 | GRM1 (0.47) | TRPV1SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | TRPV1 4718/4885SORD 3269/4885OGA 3268/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | TRPV1 4718/4885SORD 3269/4885OGA 3268/4885 |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | TRPV1 4718/4885SORD 3269/4885OGA 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.